allogeneic platelet lysate eye drops

Allogeneic platelet lysate (APL) eye drops are an investigational biologic therapy developed by St. Petersburg State Pavlov Medical University for the treatment of severe chronic ocular graft-versus-host disease (GVHD) that is refractory to conventional treatments. The therapy is produced from pooled allogeneic platelets and is rich in bioactive proteins, including platelet-derived growth factors (PDGF), epidermal growth factor (EGF), and transforming growth factor-beta (TGF-β). These components work synergistically to promote corneal epithelial healing, stabilize the tear film, and reduce inflammation on the ocular surface. A Phase 2 randomized clinical trial is currently evaluating the safety and efficacy of two different concentrations (20% and 50%) of these eye drops in patients suffering from debilitating ocular complications following allogeneic hematopoietic stem cell transplantation.

Other names

allogeneic platelet lysateAPL eye dropsallogeneic platelet lysate-St. Petersburg State Pavlov Medical University